HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

PACB

Pacific Biosciences of California, Inc. (NASDAQ)

Healthcare — Medical Devices

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument. It serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. It has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Buy 2.0 / 5 6 analysts
$1.74
+$0.06 (+3.57%)
Target: $2.46 (41.3%)
Sign in to add PACB to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$540.45M
P/E Ratio (TTM)-
Forward P/E-4.39
EPS (TTM)$-0.41
Dividend Yield-
Profit Margin-80.34%
Revenue Growth0.10%
ROE-273.55%
Debt/Equity29855.79
Recommendation Buy 2.0
Analyst Target$2.46
Analysts6
Indexes NASDAQ

Technical Indicators

RSI (14)73.4
Beta2.32
SMA 20-
SMA 40-
52-Week High$2.73
52-Week Low$1.09
50-Day Avg$1.45
200-Day Avg$1.69
Avg Volume$6.30M
Volume$5.00M

Performance Analysis

NEUTRAL

PACB presents a mixed picture with both positive and negative indicators.

~ Trading at 40% of its 52-week range.
- RSI at 73.4 indicates overbought conditions — a pullback may be due.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
~ Modest revenue growth of 0.1% year-over-year.
- Operating at a loss with -80.3% margin.
+ Wall Street consensus is "Buy" from 6 analysts.
+ Average analyst target of $2.46 implies 41.3% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:25 UTC

Back to Screener Export Report